VIT's innovative and adaptable instrument, considered the first scanning laser ophthalmoscope specifically designed for laboratory use, is capable of generating high-quality data swiftly. This investment marks DPV’s eighth from its inaugural fund.

The increasing prevalence of eye diseases like age-related macular degeneration and conditions impacting the eye, such as diabetes, correlates with an aging population. This trend is contributing to the growing demand for novel and improved medications for these issues, fuelling the global drug discovery market, which is projected to surpass $120 billion by 2030. The emergence of research tools like the VoxOne scanning laser ophthalmoscope is a response to this need.

Vox Imaging Technology, established in 2021 by Peter West and Alan Robinson, brings a wealth of innovative experience in ophthalmic imaging systems, drawn from their previous roles in industry and academia. DPV recognised the potential in the VIT team’s expertise in this promising market, along with the superior capabilities of their technology compared to existing products.

The investment from DPV will enable Vox Imaging Technology to relocate to new facilities at Discovery Park, supporting the finalisation of a working prototype and the conduction of proof-of-concept tests before its anticipated 2025 launch. The primary clientele for the company is expected to include pharmaceutical and biotechnology firms, as well as contract research organisations. Following the investment, Dr Martino Picardo, a Director at DPV, will assume the role of Interim Chairman at VIT, while Emma Palmer Foster, another DPV Director, will join Vox Imaging as an Investor Director.

Peter West, Chief Technology Officer and Founder, Vox Imaging Technology, said: “We’re gratified that Discovery Park Ventures recognised the potential impact of accurate ophthalmic imaging in early-stage research. Not only will their investment help to drive the development of our technology, but Discovery Park also offers the ideal location for us to grow the business with high-specification facilities, access to a wide network of potential partners and advisors, and a strong academic research community on our doorstep.”

Mayer Schreiber, Chairman of Discovery Park Ventures, commented: “High resolution, easy to use preclinical ophthalmic imaging will facilitate progress towards new treatments for eye-related diseases. We’re excited to invest in such a promising business that already calls Kent home and are pleased to welcome the team to Discovery Park.” 

Established by Discovery Park in 2022, Discovery Park Ventures (DPV) focuses on investments in high-potential, rapidly expanding life-science companies. The fund has recently grown to £3 million and has an ambitious plan to increase its capacity to £25 million over the next three years. DPV's investment strategy centres around innovative and disruptive technologies that align with the key areas of interest at Discovery Park. Companies receiving investment from DPV maintain robust collaborative relationships with Discovery Park, furthering their mutual goals in the life sciences sector.